Episodes

  • Use of imaging in large vessel vasculitis: EULAR 2023 update

    Use of imaging in large vessel vasculitis: EULAR 2023 update
    Jun 21 2024

    Join our host Dr. Fabian Proft, ARD's Social Media Advisor, as he discusses the updated 2023 EULAR recommendations for imaging in large vessel vasculitis (LVV) with Professor Christian Dejaco and Dr. Milena Bond, the lead authors of the manuscript. This episode covers the latest evidence on ultrasound, MRI, CT, and FDG-PET for diagnosing and monitoring LVV.

    Key highlights include:

    • Ultrasound as the first-line imaging test for giant cell arteritis.
    • Preferred imaging modalities for Takayasu arteritis.
    • Use of imaging for assessing vessel abnormalities and long-term monitoring.
    • Insights into the research agenda for imaging in large vessel vasculitides.

    Tune in to learn how these updates aim to enhance patient care and stay informed on the latest developments in rheumatology imaging. Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
    Show more Show less
    32 mins
  • Managing Systemic Lupus Erythematosus: the latest EULAR recommendations

    Managing Systemic Lupus Erythematosus: the latest EULAR recommendations
    Apr 22 2024

    This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE).

    ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: https://ard.bmj.com/content/83/1/15.

    Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
    Show more Show less
    21 mins
  • A non-pharma approach in systemic lupus erythematosus and systemic sclerosis

    A non-pharma approach in systemic lupus erythematosus and systemic sclerosis
    Oct 30 2023

    In this podcast, we discuss the evidence-based EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professor Carina Boström and Professor Ioannis Parodis, both from the Karolinska Institutet and the Karolinska University Hospital, Stockholm, Sweden, about their recent paper. Read it on the ARD website: https://ard.bmj.com/content/early/2023/08/23/ard-2023-224416

    Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page -https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
    Show more Show less
    19 mins
  • Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin

    Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin
    Feb 7 2022
    In this podcast, Dr. Truchetet discusses her work on the role of innate lymphoid cells in the fibrotic processes in systemic sclerosis (SSc) patients. The group of Dr. Truchetet found that ILC2 are crucial mediators of skin fibrosis in SSc and that combined treatment of patients with TGFb inhibitors and IL-10 might be an attractive new therapeutic approach in SSc. Read the full paper on the ARD website: https://ard.bmj.com/content/80/12/1594

    Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page (https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059).
    Show more Show less
    22 mins
  • Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

    Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases
    Jul 29 2021
    In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD's Social Media Advisor, interviews Bimba Hoyer, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Germany, and Rebecca H Haberman, Division of Rheumatology, University Grossman School of Medicine, New York, USA. They describe their works and offer their thoughts on the current situation in this area and the future. Related content: https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272

    https://ard.bmj.com/content/early/2021/06/07/annrheumdis-2021-220597
    Show more Show less
    21 mins
  • The EULAR COVID-19 database and its insights into risk factors

    The EULAR COVID-19 database and its insights into risk factors
    Mar 18 2021
    The EULAR COVID-19 database and the COVID-19 Global Rheumatology Alliance work together on shared collected data to address the most pertinent questions in regard to risks for people with rheumatic diseases and COVID-19 infection. The latest study confirms already known risk factors for more severe disease and explores associations between treatments and the risk of death.

    In this podcast, ARD’s social media editor, Dr Paul Studenic, is joined by Prof. Pedro Machado, from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK, to discuss the paper “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry” (http://dx.doi.org/10.1136/annrheumdis-2020-219498).
    Show more Show less
    26 mins
  • Predictors of disease worsening in systemic sclerosis

    Predictors of disease worsening in systemic sclerosis
    Sep 15 2020
    Capturing disease progression in SSc is challenging. Becker and colleagues addressed this problem by identifying predictors of disease worsening in the EUSTAR cohort. ARD's social media advisor Dr. Caroline Ospelt talks to Dr. Mike Becker about the results of this analysis.

    Read the paper: ard.bmj.com/content/78/9/1242
    Show more Show less
    12 mins
  • Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab

    Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab
    Aug 6 2020
    In this podcast, Dr. Paul Studenic speaks to Dr. Sofia Ramiro and Prof. Robert Landewé both engaged in clinical work in the Zuyderland Medical Center in the south of the Netherlands about their clinical study evaluating systemic glucocorticoids and Il-6 blockade as second-line treatment for COVID-19-associated cytokine storm syndrome. They tell the story of the set-up of a peculiar trial using historical patients treated with supportive care as controls to the ‘experimental’ treatment strategy during these unprecedented times of March and April 2020. Link to article: https://ard.bmj.com/content/79/9/1143

    Link to EULAR press release: https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/eular_glucocorticoids_and_il_6_receptor_can_reduce_covid19_css_related_hospital_mortality_(002).pdf
    Show more Show less
    24 mins